Cost‐effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg‐negative chronic hepatitis B

Abstract

Long-term treatment with adefovir dipivoxil is a cost-effective strategy in patients with chronic hepatitis B 'e' antigen-negative hepatitis.